Back
Agios Pharmaceuticals 10K Form
Sell
3
AGIO
Agios Pharmaceuticals
Last Price:
$35.35
Seasonality Move:
15.25%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-02 | 10Q | AGIO/Agios Pharmaceuticals Quarterly |
2023-11-02 | 10Q | AGIO/Agios Pharmaceuticals Quarterly |
2023-08-03 | 10Q | AGIO/Agios Pharmaceuticals Quarterly |
2023-05-04 | 10Q | AGIO/Agios Pharmaceuticals Quarterly |
2022-11-03 | 10Q | AGIO/Agios Pharmaceuticals Quarterly |
2022-08-04 | 10Q | AGIO/Agios Pharmaceuticals Quarterly |
Receive AGIO News And Ratings
See the #1 stock for the next 7 days that we like better than AGIO
AGIO Financial Statistics
Sales & Book Value
Annual Sales: | $26.8M |
---|---|
Cash Flow: | $-84.6M |
Price / Cash Flow: | 0 |
Annual Sales: | $28.53 |
Price / Book: | 1.24 |
Profitability
EPS (TTM): | 11.36000 |
---|---|
Net Income (TTM): | $674.3M |
Gross Margin: | $23.9M |
Return on Equity: | 71.3% |
Return on Assets: | 62.91% |
Agios Pharmaceuticals Earnings Forecast
Key Agios Pharmaceuticals Financial Ratios
-
The Gross Profit Margin over the past 11 years for AGIO is 89.26%.
-
The Selling, General & Administrative Expenses for AGIO have been equal to 447.02% of Gross Profit Margin.
-
The Research & Development expenses have been 1,101.76% of Revenue.
-
The Interest Expense is -5.45% of Operating Income.
-
Per Share Earnings over the last 13 years have been positive in 4 years.
Agios Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | AGIO |
CUSIP: | 00847X |
Website: | agios.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 8.99 |
Quick Ratio: | 8.44 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
AGIO Technical Analysis vs Fundamental Analysis
Sell
3
Agios Pharmaceuticals (AGIO)
is a Sell
Is Agios Pharmaceuticals a Buy or a Sell?
-
Agios Pharmaceuticals stock is rated a SellThe current Agios Pharmaceuticals [AGIO] share price is $35.39. The Score for AGIO is 3, which is 94% below its historic median score of 50, and infers higher risk than normal.